Clinical characteristics of hemodialysis patients with atrial fibrillation: The RAKUEN (Registry of atrial fibrillation in chronic kidney disease under hemodialysis from Niigata) study

Journal of Cardiology

Volumn 68, Issue 2, 2016, Pages 148-155

  Mitsuma, Wataru ^a   Matsubara, Taku ^a   Hatada, Katsuharu ^a   Imai, Shunsuke ^a   Saito, Noriko ^a   Shimada, Hisaki ^a   Miyazaki, Shigeru ^a  

^a Shinrakuen Hospital   (Japan)

Author keywords

Atrial fibrillation; Bleeding; Hemodialysis; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; CALCIUM; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; TRIACYLGLYCEROL; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING DISORDER; BRAIN ISCHEMIA; CAUSE OF DEATH; CLINICAL EVALUATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULONEPHRITIS; HEART DEATH; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTCOME ASSESSMENT; PRESCRIPTION; TREATMENT DURATION; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; COMPLICATION; JAPAN; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; STROKE; TIME FACTOR;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; STROKE; TIME FACTORS; WARFARIN;

EID: 84988826752     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.08.023     Document Type: Article

References (29)

1. [1] Stack, A.G., Bloembergen, W.E., Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 12 (2001), 1516–1523.
2. [2] Cheung, A.K., Sarnak, M.J., Yan, G., Berkoben, M., Heyka, R., Kaufman, A., Lewis, J., Rocco, M., Toto, R., Windus, D., Ornt, D., Levey, A.S., HEMO Study Group, Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65 (2004), 2380–2389.
3. [3] Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991), 983–988.
4. [4] Akao, M., Chun, Y.H., Wada, H., Esato, M., Hashimoto, T., Abe, M., Hasegawa, K., Tsuji, H., Furuke, K., Fushimi AF Registry Investigators, Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 61 (2013), 260–266.
5. [5] Winkelmayer, W.C., Patrick, A.R., Liu, J., Brookhart, M.A., Setoguchi, S., The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22 (2011), 349–357.
6. [6] Genovesi, S., Vincenti, A., Rossi, E., Pogliani, D., Acquistapace, I., Stella, A., Valsecchi, M.G., Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51 (2008), 255–262.
7. [7] Wizemann, V., Tong, L., Satayathum, S., Disney, A., Akiba, T., Fissell, R.B., Kerr, P.G., Young, E.W., Robinson, B.M., Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77 (2010), 1098–1106.
8. [8] Hori, M., Connolly, S.J., Zhu, J., Liu, L.S., Lau, C.P., Pais, P., Xavier, D., Kim, S.S., Omar, R., Dans, A.L., Tan, R.S., Chen, J.H., Tanomsup, S., Watanabe, M., Koyanagi, M., et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44 (2013), 1891–1896.
9. [9] Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137 (2010), 263–272.
10. [10] To, A.C., Yehia, M., Collins, J.F., Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply?. Nephrology (Carlton) 12 (2007), 441–447.
11. [11] Wiesholzer, M., Harm, F., Tomasec, G., Barbieri, G., Putz, D., Balcke, P., Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21 (2001), 35–39.
12. [12] Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
13. [13] Shen, A.Y., Yao, J.F., Brar, S.S., Jorgensen, M.B., Chen, W., Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 50 (2007), 309–315.
14. [14] Bhatt, D.L., Steg, P.G., Ohman, E.M., Hirsch, A.T., Ikeda, Y., Mas, J.L., Goto, S., Liau, C.S., Richard, A.J., Röther, J., Wilson, P.W., REACH Registry Investigators, International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006), 180–189.
15. [15] Sudlow, M., Thomson, R., Thwaites, B., Rodgers, H., Kenny, R.A., Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 352 (1998), 1167–1171.
16. [16] Devereaux, P.J., Anderson, D.R., Gardner, M.J., Putnam, W., Flowerdew, G.J., Brownell, B.F., Nagpal, S., Cox, J.L., Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 323 (2001), 1218–1222.
17. [17] Vázquez, E., Sánchez-Perales, C., Lozano, C., García-Cortés, M.J., Borrego, F., Guzmán, M., Pérez, P., Pagola, C., Borrego, M.J., Pérez, V., Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 92 (2003), 868–871.
18. [18] Vázquez, E., Sánchez-Perales, C., Borrego, F., Garcia-Cortés, M.J., Lozano, C., Guzmán, M., Gil, J.M., Borrego, M.J., Pérez, V., Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140 (2000), 886–890.
19. [19] de Castroviejo, E.V., Sánchez-Perales, C., Lozano-Cabezas, C., García-Cortés, M.J., Guzmán-Herrera, M., Borrego-Utiel, F., López-López, J., Pérez-Bañasco, V., Incidence of atrial fibrillation in hemodialysis patients. A prospective long-term follow-up study. Rev Esp Cardiol 59 (2006), 779–784.
20. [20] Hart, R.G., Halperin, J.L., Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 131 (1999), 688–695.
21. [21] Turin, T.C., Kita, Y., Rumana, N., Nakamura, Y., Takashima, N., Ichikawa, M., Sugihara, H., Morita, Y., Hirose, K., Okayama, A., Miura, K., Ueshima, H., Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988–2004. Stroke 41 (2010), 1871–1876.
22. [22] Elliott, M.J., Zimmerman, D., Holden, R.M., Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 50 (2007), 433–440.
23. [23] Chan, K.E., Lazarus, J.M., Thadhani, R., Hakim, R.M., Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20 (2009), 872–881.
24. [24] Holden, R.M., Harman, G.J., Wang, M., Holland, D., Day, A.G., Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008), 105–110.
25. [25] Shah, M., Avgil Tsadok, M., Jackevicius, C.A., Essebag, V., Eisenberg, M.J., Rahme, E., Humphries, K.H., Tu, J.V., Behlouli, H., Guo, H., Pilote, L., Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129 (2014), 1196–1203.
26. [26] Janssen, M.J., van der Meulen, J., The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Neth J Med 48 (1996), 198–207.
27. [27] Chan, K.E., Lazarus, J.M., Thadhani, R., Hakim, R.M., Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20 (2009), 2223–2233.
28. [28] Marinigh, R., Lane, D.A., Lip, G.Y., Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57 (2011), 1339–1348.
29. [29] Hirakata, H., Nitta, K., Inaba, M., Shoji, T., Fujii, H., Kobayashi, S., Tabei, K., Joki, N., Hase, H., Nishimura, M., Ozaki, S., Ikari, Y., Kumada, Y., Tsuruya, K., Fujimoto, S., et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial 16 (2012), 387–435.